Medical Management of Viral Diseases: Antivirals, Vaccines, Immunotherapy, and Supportive Care

Viral diseases are managed through a combination of direct antiviral agents, preventive vaccines, emerging immunotherapies, and supportive care. Treatment choice depends on virus, disease stage, host factors, and resistance patterns.

1. Antiviral Drugs (Direct-Acting)

Drug ClassExamplesKey Indications
Neuraminidase inhibitorsOseltamivir, zanamivir, baloxavirInfluenza A/B (treatment/prophylaxis)
Nucleoside/nucleotide analogsAcyclovir, valacyclovir, ganciclovir, tenofovirHSV, VZV, CMV, HBV, HIV
HCV protease/NS5A/polymerase inhibitorsGlecaprevir/pibrentasvir, sofosbuvir/velpatasvirHepatitis C (pan-genotypic, >95% SVR)
HIV ARTIntegrase inhibitors (bictegravir, dolutegravir) + NRTIsHIV-1 suppression (U=U)
RNA polymerase inhibitorsRemdesivir, molnupiravir, nirmatrelvir/ritonavirCOVID-19 (early outpatient/hospitalized)
Entry/fusion inhibitorsMaraviroc, enfuvirtideHIV (resistant strains)

2. Vaccines (Preventive & Therapeutic)

  • Live attenuated: MMR, varicella, rotavirus, yellow fever, LAIV (flu).
  • Inactivated: IPV, hepatitis A, rabies, IIV (flu).
  • Subunit/recombinant: HepB, HPV, SARS-CoV-2 protein (Novavax).
  • mRNA: Pfizer-BioNTech, Moderna (COVID-19); RSV (Arexvy).
  • Viral vector: J&J, AstraZeneca (COVID-19); Ebola (Ervebo).
  • Therapeutic vaccines: HPV therapeutic (in trials), HBV therapeutic.

3. Immunotherapy

  • Monoclonal antibodies: Palivizumab (RSV prophylaxis), bebtelovimab (COVID-19, historical), ansuvimab (Ebola).
  • Convalescent plasma/hyperimmune globulin: Polyclonal antibodies (limited utility, timing-critical).
  • Interferons: IFN-α (HBV, HCV historical); IFN-λ (COVID-19 trials).
  • Checkpoint inhibitors: PD-1/PD-L1 for virus-associated cancers (HPV+ HNSCC, EBV+ lymphoma, Merkel cell).

4. Supportive & Symptomatic Care

  • Antipyretics (acetaminophen), analgesics, hydration, oxygen.
  • Antihistamines (symptom relief only).
  • Respiratory support (HFNC, NIV, intubation) for severe lower respiratory infection.

Principles

  • Early antiviral initiation maximizes benefit (viral replication peak).
  • Resistance monitoring (HIV, HCV, CMV, influenza).
  • Vaccination remains the most cost-effective population-level strategy.

Rapid diagnostics (multiplex PCR, antigen tests) enable targeted therapy and infection control.

Viral Infections - Related Articles